Tirzepatide Weight Loss Timeline: What Trials Show

Quick Answer: The trials summarized here measured weight change over 72 weeks. Their averages do not provide a month-by-month forecast for you or establish when you will notice appetite changes. Review progress and symptoms with your clinician, and do not change your dose on your own.

This guide explains the study timeframes and what they can—and cannot—tell you about an individual treatment course. Trial findings should not be assumed to apply to compounded tirzepatide.

Important Safety Information & Not-FDA-Approved Disclaimer

Compounded tirzepatide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. The efficacy and safety data described in this article come from clinical trials of FDA-approved tirzepatide products (Mounjaro® and Zepbound®) and should not be assumed to apply to compounded formulations. Compounded medications may be appropriate only for patients who have a clinical need that cannot be met by an FDA-approved product, as determined by a licensed clinician.

Selected Zepbound safety information: The label describes thyroid C-cell tumors in rats; human relevance is unknown. Zepbound is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), or prior serious hypersensitivity to tirzepatide or its ingredients.

Stop Zepbound and seek immediate medical help for suspected pancreatitis or serious allergy. Persistent severe abdominal pain, sometimes reaching the back, with or without vomiting, needs prompt clinician contact. Call 911 for breathing difficulty or collapse. Inability to retain fluids needs urgent assessment.

Stop Zepbound when pregnancy is recognized. Oral contraceptive users should discuss a non-oral method or added barrier protection for four weeks after starting and after each dose increase.

This is selected guidance, not a complete risk list or instructions for every tirzepatide preparation. Review the full label and your exact prescription with your clinician.

The Titration Schedule (For Reference)

Zepbound sections 2.1–2.2 specify:

• Start at 2.5 mg weekly for four weeks; this is not a maintenance dose.
• Further increases use 2.5 mg steps after at least four weeks at the current dose.
• Weight-management maintenance options are 5, 10 or 15 mg weekly, selected for response and tolerability; 15 mg is the maximum.

There is no requirement that everyone reach the maximum at week 21. The starting-dose designation does not predict whether an individual will lose weight during initiation. Do not self-adjust or apply this branded schedule to compounded medication; confirm your written instructions with your prescriber.

For more on how tirzepatide works and its dual GIP/GLP-1 mechanism, see our complete guide to tirzepatide.

What Participants Reported Over Time

Use follow-up visits to review your actual experience rather than comparing yourself with an expected sequence of appetite, clothing-fit or symptom changes.

Early Weeks (Starting/Lower Doses)

Confirm how to take your prescription and whom to contact about symptoms. The studies summarized below do not establish a universal one- or two-week appetite-response deadline.

Middle Phase (Dose Escalation)

Record your weight trend, symptoms and any difficulties with your prescription. Ask your clinician whether a change is appropriate; a calendar alone should not determine it. Do not dismiss persistent symptoms as an expected brief reaction to a dose increase.

Longer Term (Maintenance Dose)

Discuss whether further loss or maintaining prior loss fits your health goals. A 72-week trial endpoint is not the date everyone reaches a plateau or becomes free of side effects.

For strategies to manage side effects, see our side effect management guide.

Clinical Trial Results: SURMOUNT Studies

The following figures come from the SURMOUNT clinical trials of FDA-approved tirzepatide. They describe average results across study populations over the full trial period. Individual results vary widely and are not guaranteed, and these data do not describe compounded tirzepatide.

SURMOUNT-1 Trial (72 weeks)

SURMOUNT-1 randomized 2,539 adults with obesity, or overweight plus a weight-related complication, without diabetes, to weekly tirzepatide injections or placebo for 72 weeks. The following means use the analysis that included outcomes regardless of treatment discontinuation:1

• 5 mg dose: approximately 15% average body weight reduction
• 10 mg dose: approximately 19.5% average body weight reduction
• 15 mg dose: approximately 20.9% average body weight reduction
• Placebo: approximately 3.1% average body weight reduction

These are end-of-study averages, not monthly targets. They cannot establish how much you should have lost at a particular appointment.

SURMOUNT-5 Trial (Head-to-Head With Semaglutide)

SURMOUNT-5 randomized 751 adults with obesity without type 2 diabetes in an open-label comparison of weekly injections over 72 weeks:

• Tirzepatide, maximum tolerated 10 or 15 mg: mean body-weight reduction of approximately 20.2%
• Semaglutide, maximum tolerated 1.7 or 2.4 mg: approximately 13.7%

In that specific trial, the average percentage body-weight reduction was greater in the tirzepatide group than in the semaglutide group. This finding comes from one head-to-head study of FDA-approved products; it does not describe compounded medications, and individual results vary. It is not a guarantee that any individual will lose more weight on one medication than another.

For a fuller comparison, see tirzepatide vs semaglutide.

Factors That Affect Individual Response

Your starting BMI, sleep or activity level alone cannot reliably tell you how quickly tirzepatide will change your weight. Bring your actual treatment history and goals to follow-up visits.

Information to Bring to Follow-Up

• Your prescription, dose history and any missed doses
• Weight measurements over time, rather than a single reading
• Appetite changes, digestive symptoms and ability to eat normally
• Activity limitations, sleep concerns and practical barriers to your plan

Medical History to Review

NIDDK identifies medications and health conditions among factors that can affect weight. This does not make them a validated ranking of faster or slower tirzepatide responses. Review your medical history and other medicines with your clinician instead of assigning yourself to a response category.

Nutrition Considerations

Ask your clinician or dietitian to review whether your current eating pattern meets your needs. Useful topics include protein-containing foods, overall intake, digestive tolerance and fluid needs, including any prescribed restrictions. Do not reduce food further solely to match a trial average. Persistent vomiting or inability to retain fluids needs the urgent assessment described above.

For more detail, see our diet guide for tirzepatide.

Weight Loss Plateaus

When Weight Stabilizes

A stable scale reading does not establish the cause or predict when loss will resume. Review your trend with your clinician and discuss whether maintaining prior loss or pursuing further loss fits your goals. Do not assume extra protein, water or a dose increase will end a plateau.

When to Contact Your Clinician

If weight stalls for several weeks, or if you have questions about your dose, contact your clinician. Any dose change is a clinical decision. Also reach out promptly if you experience persistent or severe side effects (see the Important Safety Information above).

For more, see our tirzepatide plateau guide.

Setting Realistic Expectations

Clinical trials of FDA-approved tirzepatide reported substantial average body-weight reductions over roughly 72 weeks, but the range across individuals was wide. Some participants lost considerably more than the average; others lost less. No outcome is guaranteed, and trial averages for FDA-approved products do not predict any individual’s result on any product, including compounded tirzepatide.

What Tirzepatide Is Not

• It is not a guarantee of any specific amount of weight loss.
• It is not a substitute for ongoing healthy eating and activity.
• It does not build muscle; resistance training and protein support that.
• Lifestyle habits do not guarantee that weight loss will persist after stopping treatment; see the withdrawal trial below.

For more, see our guide on stopping tirzepatide and maintaining results.

Maintenance After Weight Loss

In SURMOUNT-4, 670 participants were randomized after a 36-week tirzepatide lead-in to continue their maximum tolerated 10 or 15 mg dose or switch to placebo for 52 weeks. Lifestyle counseling continued in both groups.

From randomization to week 88, mean weight changed by −5.5% with continued tirzepatide and +14.0% with placebo. These percentages use week-36 weight as their starting point, not original pretreatment weight. Regain occurred despite continued lifestyle support.

The trial does not predict your individual outcome or establish a tapering plan, and it did not study compounded formulations. Discuss treatment duration, safety, follow-up and any planned interruption with your clinician. Do not stop or restart medication as an experiment to influence your weight trend; urgent stop-use instructions still apply.

Frequently Asked Questions

How quickly does tirzepatide start working?

The trial summaries here do not establish a universal onset time for appetite effects. Ask your clinician how to assess your response and when to arrange follow-up; feeling less hungry is not a prediction of a particular weight result.

How much weight will I lose on tirzepatide?

No specific amount can be promised. In trials of FDA-approved tirzepatide, participants lost a substantial percentage of body weight on average over roughly 72 weeks, with a wide range across individuals. Your result may be higher or lower, and these figures reflect FDA-approved products, not compounded tirzepatide.

What does the clinical data show at around 3 months?

The figures above describe week-72 outcomes. Do not divide them into monthly targets. Review your actual three-month trend, treatment stage and tolerability with your clinician.

Is tirzepatide more effective than semaglutide?

In the SURMOUNT-5 head-to-head trial of FDA-approved products, the average percentage body-weight reduction was greater in the tirzepatide group (about 20.2%) than in the semaglutide group (about 13.7%).2 This is one trial of FDA-approved products; it does not describe compounded medications and does not guarantee any individual’s result. Compounded tirzepatide and compounded semaglutide are not FDA-reviewed, are not generics, and are not equivalent to or interchangeable with the branded products these trials studied.

Do you lose weight every week?

Not necessarily. Weight can fluctuate week to week due to fluid shifts and other factors. Longer-term trends are more meaningful than week-to-week changes. Discuss your progress with your clinician.

What if my weight loss seems slow?

Response varies widely. If you have concerns, contact your clinician. Do not increase your dose on your own—any dose change is a clinical decision.

What are the most important risks to know?

Review the selected Zepbound warnings above and obtain complete safety instructions for your prescription. Symptoms needing urgent help should not wait for a routine weight-progress appointment.

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. The clinical data in this article come from FDA-approved tirzepatide products.

Talking With a Boca Health Clinician

Understanding the clinical data can help you have an informed conversation with a licensed clinician about whether a GLP-1/GIP medication may be appropriate for you. Treatment is individualized, and no outcome can be guaranteed.

At Boca Health, our program includes:

• Compounded tirzepatide (not FDA-approved) — see current pricing on our compounded tirzepatide page
• Oversight by licensed clinicians, with clinician-directed dosing
• Ongoing support and check-ins for questions about your treatment
• Supplies included where applicable
• Medication shipped to your door

See If You May Be a Candidate

Want to compare options? See tirzepatide vs semaglutide or learn about the dosing schedule.

---

References:

1. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387:205–216. PMID: 35658024
2. Aronne LJ, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.” N Engl J Med. 2025. doi:10.1056/NEJMoa2416394. SURMOUNT-5 publication